Cost watchdogs back Novartis’ Xolair for big new market in chronic hives

Tracy Staton

England's -effectiveness have changed their mind on . The National Institute for Health and Care Excellence decided to the asthma drug as a treatment for , after sending the drugmaker back for more data last year.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS